Shares of Elanco Animal Health Incorporated (NYSE:ELAN – Get Free Report) have been given an average rating of “Moderate Buy” by the twelve research firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $29.70.
ELAN has been the subject of several research reports. KeyCorp lifted their target price on shares of Elanco Animal Health from $29.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Piper Sandler restated an “overweight” rating on shares of Elanco Animal Health in a research note on Monday, June 29th. Weiss Ratings upgraded Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, September 4th. Morgan Stanley lifted their price objective on Elanco Animal Health from $23.00 to $26.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 22nd. Finally, TD Cowen boosted their price objective on Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, June 18th.
Check Out Our Latest Stock Analysis on Elanco Animal Health
Elanco Animal Health Trading Up 0.6%
Elanco Animal Health (NYSE:ELAN – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.07. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The business had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.31 billion. During the same period in the previous year, the firm earned $0.26 EPS. The business’s revenue was up 10.2% on a year-over-year basis. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, analysts predict that Elanco Animal Health will post 1.13 EPS for the current year.
Insider Activity at Elanco Animal Health
In other Elanco Animal Health news, insider Shiv O’Neill purchased 3,998 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were bought at an average cost of $23.58 per share, for a total transaction of $94,272.84. Following the completion of the purchase, the insider directly owned 87,832 shares of the company’s stock, valued at approximately $2,071,078.56. This trade represents a 4.77% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Michael J. Harrington purchased 5,000 shares of Elanco Animal Health stock in a transaction dated Wednesday, August 12th. The shares were acquired at an average cost of $21.82 per share, for a total transaction of $109,100.00. Following the transaction, the director directly owned 131,451 shares of the company’s stock, valued at approximately $2,868,260.82. This represents a 3.95% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 63,198 shares of company stock worth $1,473,109 over the last ninety days. Company insiders own 1.14% of the company’s stock.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the business. Anchor Investment Management LLC acquired a new stake in Elanco Animal Health during the 2nd quarter worth approximately $29,000. Integrated Wealth Concepts LLC purchased a new position in Elanco Animal Health in the 2nd quarter valued at approximately $35,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Elanco Animal Health in the second quarter worth $38,000. Root Financial Partners LLC grew its stake in shares of Elanco Animal Health by 50.7% in the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock worth $40,000 after acquiring an additional 592 shares in the last quarter. Finally, Bessemer Group Inc. increased its position in shares of Elanco Animal Health by 33.2% during the first quarter. Bessemer Group Inc. now owns 2,105 shares of the company’s stock worth $50,000 after acquiring an additional 525 shares during the period. Institutional investors and hedge funds own 97.48% of the company’s stock.
About Elanco Animal Health
Elanco Animal Health Incorporated is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio includes veterinary pharmaceuticals, vaccines, parasiticides, nutritional products and other solutions designed to prevent and treat disease, improve animal well-being and support livestock productivity.
For companion animals, Elanco offers products addressing pain, osteoarthritis, dermatological conditions, infectious diseases and flea, tick and intestinal parasite control.
Featured Stories
- Five stocks we like better than Elanco Animal Health
- CarMax Just Gave Investors a Better Reason to Believe in the Turnaround
- CoreWeave Comes With Risks: Analysts Split on What Matters Most
- Bottlenecking the Future: TSMC Prices Out the Competition
- Fervo Energy Hits Geothermal Milestone: Will It Matter For The Stock?
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
